Polyinosinic-polycytidylic acid sodium

Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.

Product information

CAS Number: 42424-50-0

Molecular Weight: 694.39

Formula: C19H27N7NaO16P2

Synonym:

Poly(I:C) sodium

Chemical Name: Polyinosinic-polycytidylic acid sodium

Smiles: [Na].NC1C=CN([C@@H]2O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]2O)C(=O)N=1.OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O |^1:0|

InChiKey: GETQKWBYQAUFQM-VRQAYDGLSA-N

InChi: InChI=1S/C10H13N4O8P.C9H14N3O8P.Na/c15-6-4(1-21-23(18,19)20)22-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17;10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;/h2-4,6-7,10,15-16H,1H2,(H,11,12,17)(H2,18,19,20);1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18);/t4-,6-,7-,10-;4-,6-,7-,8-;/m11./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: H2O : 10 mg/mL

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Polyinosinic-polycytidylic acid (20 ng/mL; 24 hours; WM793, WM278, WM239A, WM9 and 1205Lu cells) treatment strongly reduces viability from 100% in controls to 20%–50% within 24 hours. Polyinosinic-polycytidylic acid (200 ng/mL; 24 hours; 1205Lu cells) treatment induces apoptosis in 1205Lu cells. Polyinosinic-polycytidylic acid (3 ng/mL; 24 hours; 1205Lu cells) treatment induces IFN-β expression in melanoma cells. Silencing of RIG-I and MDA-5 confirmed that induction of IFN-β by Polyinosinic-polycytidylic acid required RIG-I and MDA-5, respectively, and that required IPS-1. Polyinosinic-polycytidylic acid (5 ng/mL; 24 hours; 1205Lu cells) treatment reveals active subunits of caspase-9 and caspase-8 in melanoma cells. Polyinosinic-polycytidylic acid sodium is prepared for injection by resuspending in sterile saline, heating to 50 °C at a concentration of 2 mg/ml to ensure complete solubilisation and then allowing to cool naturally to room temperature to ensure proper annealing of double-stranded RNA. Poly I:C is stored at -20 °C until use.

In Vivo:

Polyinosinic-polycytidylic acid treatment inhibits tumor growth in NOD/SCID immunodeficient mice injected with 1205Lu cells. The level of human DNA is 50% lower in mice treated with Polyinosinic-polycytidylic acid.

References:

1. Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119(8):2399-411.
2. Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10(12):1219-23.
3. Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24(6):996-1007.

Products are for research use only. Not for human use.